News and Announcements
Bionomics New Alzheimer’s Drug Candidate
- Published December 14, 2012 4:42PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bionomics Limited (ASX:BNO, ADR:BMICY) has identified a novel compound with promising properties as a potential new treatment for Alzheimer’s disease. Following validation in preclinical models of memory deficit in Alzheimer’s disease, Bionomics has formally nominated BNC375 as its drug candidate. BNC375 is currently on a dual track, as Bionomics prepares for both clinical trials and strategic partnering.
BNC375 is proprietary to Bionomics and is a positive allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), an important target for the improvement of memory and learning deficits that occur in illnesses like Alzheimer’s disease.
——-
To view the full article, please click the link below.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
